Jorge A. Tavel

3.6k total citations · 1 hit paper
43 papers, 2.5k citations indexed

About

Jorge A. Tavel is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jorge A. Tavel has authored 43 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 19 papers in Virology and 15 papers in Epidemiology. Recurrent topics in Jorge A. Tavel's work include HIV Research and Treatment (19 papers), HIV/AIDS Research and Interventions (13 papers) and HIV-related health complications and treatments (10 papers). Jorge A. Tavel is often cited by papers focused on HIV Research and Treatment (19 papers), HIV/AIDS Research and Interventions (13 papers) and HIV-related health complications and treatments (10 papers). Jorge A. Tavel collaborates with scholars based in United States, Australia and United Kingdom. Jorge A. Tavel's co-authors include H. Clifford Lane, Henry Masur, Rong Deng, Julia A. Metcalf, Richard T. Davey, Mauricio Maia, Tracy Burgess, Joseph A. Kovacs, Michael A. Derby and Michael A. Polis and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and PLoS ONE.

In The Last Decade

Jorge A. Tavel

43 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge A. Tavel United States	21	632	528	453	440	393	43	2.5k
Vivek Jain United States	29	1.4k 2.3×	526 1.0×	514 1.1×	543 1.2×	369 0.9×	118	4.3k
Jacqueline Parkin United Kingdom	24	392 0.6×	654 1.2×	381 0.8×	613 1.4×	778 2.0×	56	2.8k
Reinhold E. Schmidt Germany	37	510 0.8×	478 0.9×	191 0.4×	276 0.6×	974 2.5×	100	4.2k
Priya Duggal United States	37	831 1.3×	800 1.5×	262 0.6×	1.2k 2.8×	437 1.1×	123	3.7k
John Kim United States	32	1.3k 2.0×	610 1.2×	219 0.5×	653 1.5×	366 0.9×	119	3.9k
Susan E. Wilson United States	27	1.2k 1.9×	332 0.6×	297 0.7×	238 0.5×	425 1.1×	81	3.0k
Frank Hulstaert Belgium	30	409 0.6×	791 1.5×	384 0.8×	381 0.9×	667 1.7×	108	3.6k
Jason Li United States	18	869 1.4×	432 0.8×	860 1.9×	492 1.1×	600 1.5×	38	2.8k
Robert Zangerle Austria	29	378 0.6×	833 1.6×	698 1.5×	851 1.9×	268 0.7×	81	2.4k
Xiangrong Kong United States	33	657 1.0×	631 1.2×	215 0.5×	426 1.0×	121 0.3×	102	3.2k

Countries citing papers authored by Jorge A. Tavel

Since Specialization

Citations

This map shows the geographic impact of Jorge A. Tavel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge A. Tavel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge A. Tavel more than expected).

Fields of papers citing papers by Jorge A. Tavel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge A. Tavel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge A. Tavel. The network helps show where Jorge A. Tavel may publish in the future.

Co-authorship network of co-authors of Jorge A. Tavel

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge A. Tavel. A scholar is included among the top collaborators of Jorge A. Tavel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge A. Tavel. Jorge A. Tavel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lim, Jeremy J., Michael A. Derby, Yaping Zhang, et al.. (2017). A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 61(8). 11 indexed citations

2.

Deng, Rong, Mauricio Maia, Jeremy J. Lim, et al.. (2017). Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. Clinical Pharmacokinetics. 57(3). 367–377. 22 indexed citations

3.

Grady, Christine, Giota Touloumi, A. Sarah Walker, et al.. (2017). A randomized trial comparing concise and standard consent forms in the START trial. PLoS ONE. 12(4). e0172607–e0172607. 22 indexed citations

4.

Ishida, Julie H., Anita Patel, Aneesh K. Mehta, et al.. (2016). Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrobial Agents and Chemotherapy. 61(2). 75 indexed citations

5.

Tavel, Jorge A., Jing Qin, Xiao Liu, et al.. (2012). Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. PLoS ONE. 7(3). e24243–e24243. 78 indexed citations

6.

Tavel, Jorge A., Chiung‐Yu Huang, Julia A. Metcalf, et al.. (2010). Interferon-α Produces Significant Decreases in HIV Load. Journal of Interferon & Cytokine Research. 30(7). 461–464. 33 indexed citations

7.

Tavel, Jorge A., et al.. (2010). Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study. PLoS ONE. 5(2). e9334–e9334. 13 indexed citations

8.

Smolskis, Mary, et al.. (2009). Development and Implementation of Clinical Trial Protocol Templates at the National Institute of Allergy and Infectious Diseases. Clinical Trials. 6(4). 386–391. 2 indexed citations

9.

Hahn, Barbara, Catherine Rehm, Joseph W. Adelsberger, et al.. (2008). The Effect of Continuous Versus Pericycle Antiretroviral Therapy on IL-2 Responsiveness. Journal of Interferon & Cytokine Research. 28(7). 455–462. 1 indexed citations

10.

Sereti, Irini, Peter Sklar, Meena S. Ramchandani, et al.. (2007). CD4⁺T Cell Responses to Interleukin‐2 Administration in HIV‐Infected Patients Are Directly Related to the Baseline Level of Immune Activation. The Journal of Infectious Diseases. 196(5). 677–683. 10 indexed citations

11.

Pace, Christine A., Christine Grady, David Wendler, et al.. (2006). Post-trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study. AIDS Research and Human Retroviruses. 22(9). 837–841. 16 indexed citations

12.

Pace, Christine A., Ezekiel J. Emanuel, Theshinee Chuenyam, et al.. (2005). The Quality of Informed Consent in a Clinical Research Study in Thailand. IRB Ethics and Human Research. 27(1). 9–9. 37 indexed citations

13.

Morgan, Richard A., Robert Walker, Charles S. Carter, et al.. (2005). Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. Human Gene Therapy. 0(0). 620347321–620347321. 2 indexed citations

14.

Arduino, Roberto C., Esteban C. Nannini, Shannon Schrader, et al.. (2004). CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. Clinical Infectious Diseases. 39(1). 115–122. 31 indexed citations

15.

Penzak, Scott, Edward P. Acosta, Maria L. Turner, Jorge A. Tavel, & Henry Masur. (2004). Antiretroviral Drug Content in Products from Developing Countries. Clinical Infectious Diseases. 38(9). 1317–1319. 9 indexed citations

16.

Tavel, Jorge A., Irini Sereti, Robert Walker, et al.. (2003). A Randomized, Double‐Blinded, Placebo‐Controlled Trial of Intermittent Administration of Interleukin‐2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus. The Journal of Infectious Diseases. 188(4). 531–536. 12 indexed citations

17.

Tavel, Jorge A., et al.. (2002). Regulatory approvals in a large multinational clinical trial. Controlled Clinical Trials. 23(1). 59–66. 11 indexed citations

18.

Kovacs, Joseph A., Richard A. Lempicki, Igor A. Sidorov, et al.. (2001). Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. The Journal of Experimental Medicine. 194(12). 1731–1741. 181 indexed citations

19.

Ruxrungtham, Kiat, Surapol Suwanagool, Jorge A. Tavel, et al.. (2000). A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS. 14(16). 2509–2513. 30 indexed citations

20.

Tavel, Jorge A., Kirk D. Miller, & Henry Masur. (1999). Guide to Major Clinical Trials of Antiretroviral Therapy in Human Immunodeficiency Virus‐Infected Patients: Protease Inhibitors, Non‐Nucleoside Reverse Transcriptase Inhibitors, and Nucleotide Reverse Transcriptase Inhibitors. Clinical Infectious Diseases. 28(3). 643–676. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact